Table 1.
Demographic and clinical characteristics
| Male survivors (n=5640) | Female survivors (n=5298) | |
|---|---|---|
| Age at diagnosis (years) | ||
| <5 | 2085 (37%) | 2048 (39%) |
| 5-9 | 1254 (22%) | 1012 (19%) |
| 10-14 | 1287 (23%) | 1225 (23%) |
| 15-20 | 1014 (18%) | 1013 (19%) |
| Year of diagnosis | ||
| 1970-79 | 1001 (18%) | 976 (18%) |
| 1980-89 | 2185 (39%) | 2087 (39%) |
| 1990-99 | 2454 (44%) | 2235 (42%) |
| Original cancer diagnosis | ||
| Acute lymphoblastic leukaemia | 1123 (20%) | 1120 (21%) |
| Other leukaemias | 300 (5%) | 297 (6%) |
| CNS tumour | 799 (14%) | 772 (15%) |
| Hodgkin's lymphoma | 634 (11%) | 653 (12%) |
| Non-Hodgkin lymphoma | 800 (14%) | 402 (8%) |
| Kidney tumour | 385 (7%) | 453 (9%) |
| Neuroblastoma | 493 (9%) | 525 (10%) |
| Soft-tissue sarcoma | 352 (6%) | 338 (6%) |
| Bone tumour | 754 (13%) | 738 (14%) |
| Alkylating or DNA interstrand crosslinking drug | ||
| None | 2427 (43%) | 2461 (46%) |
| Busulfan | 62 (1%) | 54 (1%) |
| Carmustine | 144 (3%) | 112 (2%) |
| Carboplatin | 158 (3%) | 120 (2%) |
| Cisplatin | 455 (8%) | 468 (9%) |
| Chlorambucil | 5 (<1%) | 11 (<1%) |
| Chlormethine | 244 (4%) | 255 (5%) |
| Cyclophosphamide | 2549 (45%) | 2216 (42%) |
| Dacarbazine | 225 (4%) | 228 (4%) |
| Ifosfamide | 320 (6%) | 275 (5%) |
| Lomustine | 69 (1%) | 62 (1%) |
| Melphalan | 40 (1%) | 44 (1%) |
| Procarbazine | 432 (8%) | 496 (9%) |
| Temozolomide | 1 (<1%) | 2 (<1%) |
| Thiotepa | 21 (<1%) | 24 (<1%) |
| Unknown | 64 (1%) | 64 (1%) |
| Radiotherapy* | ||
| None | 4713 (84%) | 4369 (82%) |
| Neck | 135 (2%) | 59 (1%) |
| Chest | 644 (11%) | 736 (14%) |
| Arms or legs | 148 (3%) | 134 (3%) |
| Sterilising procedure | 144 (3%) | 464 (9%) |
| Pregnancy | 1694 (30%) | 2455 (46%) |
| Livebirth | 1425 (25%) | 2028 (38%) |
Data are n (%).
*
The study population excluded individuals treated with cranial or pelvic radiotherapy, including those exposed to high-dose scatter radiation to the pelvis (primary treatment fields were adjacent to the pelvis).